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G protein coupled receptors (GPCRs) were first characterized as signal transducers that
elicit downstream effects through modulation of guanine (G) nucleotide-binding proteins.
The pharmacotherapeutic exploitation of this signaling paradigm has created a drug-
based field covering nearly 50% of the current pharmacopeia. Since the groundbreaking
discoveries of the late 1990s to the present day, it is now clear however that GPCRs
can also generate productive signaling cascades through the modulation of β-arrestin
functionality. β-Arrestins were first thought to only regulate receptor desensitization and
internalization – exemplified by the action of visual arrestin with respect to rhodopsin
desensitization. Nearly 20 years ago, it was found that rather than controlling GPCR
signal termination, productive β-arrestin dependent GPCR signaling paradigms were
highly dependent on multi-protein complex formation and generated long-lasting cellular
effects, in contrast to G protein signaling which is transient and functions through
soluble second messenger systems. β-Arrestin signaling was then first shown to
activate mitogen activated protein kinase signaling in a G protein-independent manner
and eventually initiate protein transcription – thus controlling expression patterns of
downstream proteins. While the possibility of developing β-arrestin biased or functionally
selective ligands is now being investigated, no additional research has been performed
on its possible contextual specificity in treating age-related disorders. The ability
of β-arrestin-dependent signaling to control complex and multidimensional protein
expression patterns makes this therapeutic strategy feasible, as treating complex age-
related disorders will likely require therapeutics that can exert network-level efficacy
profiles. It is our understanding that therapeutically targeting G protein-independent
effectors such as β-arrestin will aid in the development of precision medicines with
tailored efficacy profiles for disease/age-specific contextualities.
Keywords: β-arrestin signaling, ligand ‘bias’, GPCRs, age-related disorders, precision, tailored efficacy
Abbreviations: α2A-AR, α2A-adrenergic receptor; AD, Alzheimer’s disease; AT1aR, angiotensin II type 1A receptor; Ang II,
angiotensin II; β2AR, β2-adrenergic receptor; cAMP, cyclic adenosine monophosphate; DDR, DNA damage response; GLP-
1, glucagon-like peptide 1; GLP-1R, GLP1 receptor; GPCR, G protein coupled receptor; GRK, G protein coupled receptor
kinase; GTP, guanosine triphosphate; IRS1, insulin receptor substrate-1; MAPK, mitogen activated protein kinase; NF-κB,
nuclear factor-κB; PK, protein kinase; PTH, parathyroid hormone; PTH1R, parathyroid hormone 1 receptor; ROS, reactive
oxygen species; SII, Sar1, Ile4, Ile8-AngII; T2DM, type II diabetes mellitus.
Frontiers in Pharmacology | www.frontiersin.org 1 November 2018 | Volume 9 | Article 1369
fphar-09-01369 November 27, 2018 Time: 16:27 # 2
van Gastel et al. β-Arrestin Signaling in Aging
INTRODUCTION
The β-arrestin family comprises four members: visual arrestins
(arrestin1 and arrestin4) and the non-visual arrestins (β-arrestin1
and β-arrestin2, also referred to as arrestin2 and arrestin3,
respectively). Furthermore, an α-arrestin family, structurally
related to the β-arrestins has been identified (Chutkow et al.,
2010). To provide a more therapeutically-targeted discussion
in this review we will focus on the β-arrestins 1 and -2,
which are ubiquitously expressed in most mammalian tissues
and cell types (Feng et al., 2011). Heptahelical transmembrane
GPCRs, were originally thought to be a member of a three-
part functional signaling system: (1) the receptor detecting
ligands in the extracellular milieu, (2) a heterotrimeric (αβγ)
G protein that dissociates into α-subunits bound to guanosine
triphosphate (GTP) and βγ-subunits, after interaction with the
ligand-bound GPCR, and (3) an effector interacting with the
dissociated G protein subunits (α or βγ) to generate soluble small
molecule second messengers. This GPCR-G protein interaction
is catalytic, i.e., one receptor can sequentially activate multiple
G proteins either of the same or of a different type. GPCR
signaling through G proteins is terminated after serine-threonine
phosphorylation of the receptors, both by members of the GPCR
kinase family and second messenger-activated protein kinases
such as protein kinase A and C. This is followed by arrestin
binding (β-arrestins1 or 2), which sterically inhibits further G
protein activation (Freedman and Lefkowitz, 1996). Next, the
ligand-bound receptor can be internalized through an arrestin-
dependent engagement of clathrin-coated pits (Ferguson et al.,
1996; Goodman et al., 1996), after which the receptors are either
dephosphorylated and recycled back to the cell surface or targeted
for lysosomal degradation if a potent ligand stimulation level
persists (Yu et al., 1993).
While this canonical description of GPCR signaling still
largely holds true, this is not where GPCR signaling ends.
Luttrell et al. (1999) discovered that β-arrestin becomes part of a
multi-protein signaling complex (often termed a ‘receptorsome’)
which functions both to target the receptor-kinase complex
to clathrin-coated pits and additionally to recruit activated
non-receptor tyrosine kinase c-Src to the plasma membrane.
This ‘receptorsome’ formation process engenders a receptor-
based capacity to induce a novel signaling cascade distinct
from the G protein-dependent paradigm. Thus, it was elegantly
demonstrated that β-arrestins did not only ‘arrest’ G protein
signaling, but transformed the signaling activity and initiated
supplementary signaling cascades where the ‘desensitized’
receptor functioned as a part of a mitogenic signaling complex
(Luttrell et al., 1999). Additionally, while G protein-dependent
signaling is essentially a transient catalytic process which
generates soluble small molecule second messenger products,
it is evident that β-arrestin-dependent signaling can engender
highly characteristic and translatable transcriptomic phenotypes,
presumably via the formation of more self-reinforced, complex,
higher-order multi-protein signaling interactomes (Maudsley
et al., 2015, 2016) similar to the ‘encryptome’ complexes proposed
for growth factor receptor signaling (Martin et al., 2009). This
GPCR interactome capacity for regulating complex transcription
patterns, thus revealed the ability for β-arrestin-dependent
signaling to create discrete, reinforced coherent patterns of long-
term signal transduction. This new signaling paradigm engenders
a feasible mechanism for receptor-based cell/tissue engineering
independent of traditional GPCR signaling modalities. Since
this discovery, considerable research has been undertaken to
further investigate the functional role(s) of β-arrestin, beyond its
function in receptor desensitization, and has thus rekindled the
concept of ‘Agonist Trafficking’ in the new form of drug-focused
‘Biased’ signaling (Kenakin, 1995; Andresen and Luttrell, 2011).
GPCR Biased Signaling
The past two decades of GPCR biology research has reshaped
the world of receptor signaling and pharmacotherapeutics via
the maturation of two critical concepts: (1) receptor signaling
pluridimensionality (Maudsley et al., 2005) and (2) ligand
bias (Luttrell and Kenakin, 2011). The effective exploitation of
these two facets of receptor functionality will likely facilitate
the development in the future of more effective GPCR-based
therapeutics (i.e., higher functional specificity and reduced ‘off-
target’ actions) (Luttrell and Kenakin, 2011). Pluridimensional
efficacy of GPCRs refers to the discovery that these receptors
signal via multiple G protein and non-G protein effectors, and can
thus adopt multiple ‘active’ states. Essentially, this also introduces
the concept that a GPCR is never truly quiescent and simply
exists in different proportions of various active state complexes
in distinct cellular sub-compartments. The stable interactions
between GPCRs and β-arrestin enable the formation of receptor-
based signal-specific interactomes. Here we can potentially term
these structures ‘encryptomes’ – the specific protein stoichiometry
essentially ‘encrypts’ the specificity of the downstream intended
signal – and potentially the ‘choice’ of the encryptome-stabilizing
ligand. The specific composition of the GPCR encryptome
therefore defines its subsequent interactibility with protein- and
lipid kinases, phosphatases, ubiquitin ligases, regulators of small
G proteins, and other novel effectors (Maudsley et al., 2005;
Luttrell and Gesty-Palmer, 2010; Shenoy and Lefkowitz, 2011).
The concept of signaling selectivity or ligand bias suggests
that distinct ligands may alter the conformational equilibrium
of the receptor in a manner distinct from the endogenous
ligand, allowing the receptor to couple to a specific subset of its
downstream effectors (Wei et al., 2003; Kenakin, 2007; Kenakin
and Miller, 2010; Luttrell and Kenakin, 2011; Maudsley et al.,
2012). This functional selectivity carries with it the promise of
a revolutionary change for drug development: increasing the
potential for new, more effective drugs, but also the knowledge
that drug efficacy needs to be comprehensively characterized
in order to avoid unintended side effects. In the context of
the GPCR encryptome, ligand bias results as a function of the
protein stoichiometric composition of this. Different protein
components chaperoning and interacting with the core GPCR
will thus determine the interaction/efficacy profile of the ligand
attempting to interact and stabilize the particular encryptome.
While signaling bias using functionally selective xenobiotic
ligands has been a topic of ongoing research for nearly two
decades, it has become clear that natural ligand bias also occurs
for GPCRs and likely represents another physiological level of
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receptor signaling complexity. In discussing the natural biased
agonism of chemokine receptors (CCRs), Zidar et al. (2009)
reinforce the posit that this selectivity is not merely a product of
synthetic pharmacology (Kohout et al., 2004). In their research,
Zidar et al. (2009) found that the endogenous chemokine ligands
CCL19 and CCL21 for the CCR7 receptor, demonstrate a
striking difference in activation of the GRK/β-arrestin2 system,
despite of their similarity in promoting G protein stimulation
and chemotaxis. Only CCL19 promotes desensitization of
endogenous CCR7 in the human T cell lymphoma cell line
H9 (Kohout et al., 2004), and causes fourfold more ERK1/2
phosphorylation than CCL21, through a β-arrrestin2 dependent
mechanism (Kohout et al., 2004; Zidar et al., 2009; Zidar, 2011).
Endogenous ligand bias has also been shown for the
Angiotensin II type 1 receptor (AT1R), which is physiologically
implicated in the development of hypertension and the natural
aging process (Mattson and Maudsley, 2009). Further research in
AT1R, indicates that only a subset of AT1R signaling pathways
are detrimental, thus by using biased ligands which inhibit these
detrimental pathways, it may be possible to promote and enhance
beneficial drug-based effects (Galandrin et al., 2016). Angiotensin
peptide (1–7) [Ang(1–7)], which lacks the Angiotensin II (Ang
II) critical C-terminal phenylalanine residue due to angiotensin-
converting enzyme 2 (ACE2)-dependent cleavage is described
to cause vasodilatory and cardioprotective effects (Santos et al.,
2003, 2013). Ang(1–7) fails to promote G protein activation,
behaving as a competitive antagonist for Ang II/Gαi and Ang
II/Gαq pathways, it however selectively promotes β-arrestin
activation (Galandrin et al., 2016). These researches explain that
in nature, ligand bias has likely been exploited even before
scientist have begun to uncover the clinical uses of ligand bias,
underlining its importance.
β-Arrestin Modulates Downstream
Signaling of GPCRs Through Complex
Assembly Regulation
As mentioned previously, β-arrestin can affect GPCR signaling
in a manner independent of G protein-signaling that involves
the physical scaffolding of multiple signal transduction proteins.
Thus, it stands to reason that the signaling functionality of
β-arrestin1 and 2 can be effectively interpreted via the analysis of
the physical interactomes associated with these multidimensional
transducers (Figures 1, 2). To assess the current state of
the metadata concerning the known functional interactomes
of the β-arrestin1 (Figure 1A) and β-arrestin2 (Figure 1B)
we extracted binding partner identities from BioGrid1, HPRD
(Human Protein Reference Database2), IntAct3, MINT (The
Molecular INTeraction Database), STRING4, DIP (Database of
Interacting Proteins5) and CORUM6. The cumulated known







in Supplementary Tables S1, S2, respectively. The diversity of
subcellular distribution (Figure 1C – β-arrestin1; Figure 1D –
β-arrestin2) and molecular function (Figure 1E – β-arrestin1;
Figure 1F – β-arrestin2) of these interactors were categorized
using Ingenuity Pathway Analysis (IPA)-based annotation.
Perhaps the strongest divergence in cellular distribution of
β-arrestin-specific binding partner between the two isoforms lies
in the stronger plasma membrane representation of β-arrestin1
binding partners compared to β-arrestin2. In a similar regard,
the greatest distinction of β-arrestin binding partner functionality
resided in the much stronger ion channel function of β-arrestin1-
binding partners compared to partners of β-arrestin2. To gain
a signaling-based appreciation of the known β-arrestin-based
interactomes, an IPA canonical signaling pathway investigation
of the known binding partners (Figure 1G – β-arrestin1;
Figure 1H – β-arrestin2) was carried out. Amongst the top 20
most strongly-populated signaling pathways it was evident that
the β-arrestin1 binding cohort demonstrated a more profound
propensity for G protein-associated functionality and cell cycle
regulation compared to β-arrestin2. However, when the degree
of potential signaling pathway overlap was assessed for the
two curated β-arrestin interactomes (Figure 1I – β-arrestin1;
Figure 1J – β-arrestin2) it was clear that a more interactive and
closely associated functional network of activity was predicted
for β-arrestin2. Such data suggests perhaps that β-arrestin2 may
control a more coherent signaling response away from plasma
membrane-associated receptors (see Figure 1D). This distinction
in interactome coherence was also continued when the two
β-arrestin interactome datasets were assessed using the STRING
interaction platform (Figure 2A – β-arrestin1; Figure 2B –
β-arrestin2). Hence, with respect to the network statistics of the
two interactomes, the β-arrestin2-specific functional network,
compared to the β-arrestin1 network, possessed a greater average
node degree, a stronger local clustering coefficient and a
more significant protein–protein interaction (PPI) enrichment
probability. The natural language processing informatic platform
GeneIndexer was employed to assess the relative strength
of association between proteins β-arrestin1 or β-arrestin2
interactome datasets and gerontological biomedical concept
terms. GeneIndexer7 enables the identification of biomedical
text items, i.e., Gene Symbol identifiers of proteins, that possess
latent semantic associations with the input interrogator concept
term (i.e., Ageing, Aging, Senescence, Senescent, Elderly, Elder,
Longevity). Latent semantic analysis is a natural language
processing data extraction mechanism (Landauer et al., 2004)
that exploits the concept of ‘Swanson Linking’ (Bekhuis, 2006) to
identify cryptic connections between natural language concepts
(i.e., Ageing, Aging etc. . ..) and specific text entities, in this
case Gene Symbol targets identified using the database of
gene-word documents assembled in the GeneIndexer database
(Cashion et al., 2013). GeneIndexer contains over 1.5 million
Medline abstracts corresponding to over 21,000 mammalian
genes (Cashion et al., 2013). GeneIndexer extracts both
explicit and implicit gene-to-keyword (e.g., Aging) relationships
from the literature using Latent Semantic Indexing (LSI:
7https://geneindexer.com/
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Homayouni et al., 2005). GeneIndexer scores individual proteins
according to the strength of the association with the keyword
query (e.g., Aging), whereby a Cosine Similarity (Landauer
et al., 2004) score >0.2 typically indicates an explicit association
(i.e., the word actually appears in the protein-related PubMed
abstract), while a score between 0.1 and 0.2 typically indicates
an implied relationship (Homayouni et al., 2005). Therefore
using a basal Cosine Similarity cut-off of 0.1 we were able
to assess the group (β-arrestin1 or 2 interactome) strength of
correlation between the detailed aging-related interrogator terms
(Figure 3) and the interactome datasets by summing the various
individual protein Cosine Similarity scores extracted for each
implicitly and explicitly-associated proteins from the interactome
lists for each given gerontological concept input. One of the
biggest challenges for the machine-based analysis of human-
generated text concerns the vagaries of term use, e.g., authors
FIGURE 1 | Continued
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FIGURE 1 | Ingenuity pathway analysis of β-arrestin1 and 2 interactome. The interactors of a protein are indicative of its function. Thus, to further investigate the
function of β-arrestin1 we extracted these from seven sources: BioGrid (https://theBioGrid.org/), HPRD (Human Protein Reference Database: http://www.hprd.org/),
IntAct (https://www.ebi.ac.uk/intact/), MINT (The Molecular INTeraction Database), STRING (https://string-db.org/), DIP (Database of Interacting Proteins:
http://dip.mbi.ucla.edu/dip/), and CORUM (http://mips.helmholtz-muenchen.de/corum/). This resulted in a list of proteins which are proven interactors of β-arrestin1
(445) and 2 (625). (A,B) Shows the distribution of the aforementioned databanks for β-arrestin1 and 2 respectively. This dataset was further analyzed using Ingenuity
Pathway Analysis (IPA). Where we extracted the following information: (C,D) the subcellular distribution – categorized in an unbiased manner using IPA protein
annotation – of the interactors: Plasma Membrane, Nucleus, Cytoplasm, and Extracellular space, i, for β-arrestin1 and 2 respectively; (E,F) the functional
annotation – again performed using unbiased IPA-based classification – of the interacting proteins: Cytokine, Enzyme, GPCR, growth factor, ion channel, kinase,
peptidase, phosphatase, transcription regulator, translation regulator, transmembrane receptor, and transporter, β-arrestin1 and 2 respectively; and the Top 20
Canonical Pathways, β-arrestin1 and 2 respectively, related to this dataset organized in (G,H) a stacked bar chart, and (I,J) a network representation with a cut-off of
15 common genes between pathways, to increase the stringency, where the numbers depicted represent the amount of common proteins between the pathways.
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FIGURE 2 | Analysis of β-arrestin1 and 2 interactome using STRING Interaction Network. To further analyze the networks of (A) β-arrestin1 and (B) β-arrestin2,
STRING was used. To increase the stringency of the analysis the following settings were used: for Active Interaction Sources only “Experiments” and
“Co-expression” were selected indicating we are only interested in data which is the result of experiments or are known to co-express, this to remove hypothetical
data and suggestions. The minimum required interaction score was set to the highest level (0,9), and all unconnected nodes were removed from the network.
may use divergent syntactic entities (words) to describe the
same concepts (e.g., Aging or Ageing, Elderly or Elder). Hence
to generate the most comprehensive LSI-based appreciation of
gene-keyword associations we used a broad range of synonyms to
extract the most amount of Gene Symbol data. Using this range
of input terms (Aging, Ageing, Senescence, Senescent, Elderly,
Elder, Longevity) we found that, using the cumulated Cosine
Similarity scores for the interactome proteins associated with
these input gerontological concept terms, for the majority of the
terms (Aging, Ageing, Senescence, Senescent, and Longevity) a
greater total association of the βarrestin2 interactome proteins
with these concepts was observed compared to the βarrestin1
interactomes (Figure 3 and Supplementary Table S3). These
unbiased results are effectively concordant with our previously
derived STRING interactome analyses. This suggests, in line
with recent reports (Luttrell et al., 2018b), that highly specific
and contextual biological functionalities are likely attributable to
either βarrestin1 or 2. Therefore, it seems that indeed a potential
bias for β-arrestin2-dependent signaling may occur with respect
to the specific context of aging. In the following sections we
will discuss how, with specific reference to hypothesis-driven
experimentation, the downstream signalers can be influenced by
β-arrestin1 or β-arrestin2 interactome activity and subcellular
distribution.
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FIGURE 3 | Role of β-arrestins in aging through GeneIndexer analysis of
interactome metadata. Reanalysis of the obtained interactomes for β-arrestin1
(ARRB1) and β-arrestin2 (ARRB2), using aging-related interrogation terms with
GeneIndexer, in a manner similar to that described previously (Chadwick et al.,
2012). The following interrogation terms were used: Ageing, Aging,
Senescence, Senescent, Elderly, Elder, and Longevity (i.e., long life). These
terms (inclusive of most common spellings and synonyms) were used to
obtain as much information as possible as human-generated text descriptions
using natural language are often variant between research groups/authors. As
seen in previous bioinformatics analyses these interrogation terms all give
different results. In this figure, it becomes clear that β-arrestin2 has a stronger
connection to aging compared to β-arrestin1, with the exception of the
interrogation terms Elderly and Elder. For the generation of this figure, the
cosine similarity between the top 10 proteins and every interrogation term was
averaged in order to create this table. The cosine similarity scores linking the
proteins to each word are listed in Supplementary Table S3.
Non-receptor Tyrosine Kinase c-Src
As mentioned previously, β-arrestins also function as
downstream signal transducers of GPCRs, allowing the
formation of signal/function-specific encryptomes with a
wide variety of signaling proteins, including c-Src family
tyrosine kinases and components of the ERK1/2 and JNK3 (Jun
N-terminal kinases 3) MAP kinase cascades (Luttrell et al., 1999;
Luttrell and Lefkowitz, 2002). Through the recruitment of these
kinases to GPCRs after agonist-binding, β-arrestins grant distinct
signaling activities upon the receptor – discriminating them
physically from G protein-dependent functional GPCR forms
(Luttrell and Lefkowitz, 2002). This paradigm was illuminated
by the initial observation that β-arrestin can directly bind to Src
family kinases and recruit them to agonist-occupied GPCRs.
Stimulation of β2 adrenergic receptors (β2AR) triggered the
co-localization of the receptor with both endogenous β-arrestins
and Src kinases in clathrin-coated pits (Luttrell et al., 1999).
This reflected the assembly of the prototypic signal-encrypted
receptor-protein complex. These GPCR-based encryptomes have
also been seen in other research where β-arrestins recruited
Src to the neurokinin-1 receptors in KNRK cells (DeFea et al.,
2000) and Src family kinases Hck and Fgr to the C-X-C motif
chemokine-1 receptor (CXCR1) in neutrophils (Barlic et al.,
2000).
Mitogen Activated Protein (MAP) Kinases
The MAP kinases are a family of serine/threonine kinases
involved in the transmission of external signals regulating cell
division, growth, differentiation, and apoptosis. Mammalian cells
contain three major categories of MAP kinases: ERKs, JNKs,
and p38/HOG1 MAP kinases (Pearson et al., 2001). In 2000,
it became clear that β-arrestins have the ability to function
as scaffold proteins for some MAP kinase units. In KNRK
cells the stimulation of proteinase-activated receptor 2 (PAR2)
promotes encryptome formation containing the internalized
receptor, β-arrestin1, Raf-1, and activated ERK1/2, which is
required for ERK activation (DeFea et al., 2000). Similar results
have been gained for the angiotensin II type 1A receptor
(AT1aR) in HEK293 and COS-7 cells, where stimulation resulted
in encryptome formation containing the receptor, β-arrestin2,
and ERK cascade component kinases: cRaf-1, MEK1 (Mitogen
Activated Kinase Kinase 1) and ERK2 (Luttrell et al., 2001).
β-Arrestins can sequester ERK in the cytosol, by scaffolding
Raf1, MKK1 and ERK (Luttrell et al., 2001). In this manner
β-arrestin also scaffolds JNK1/2 through mitogen-activated
protein kinase kinase (MKK) 4 and 7 (Kook et al., 2013).
Furthermore, the activation of p38 signaling also appears to
be dependent on β-arrestin (Sun et al., 2002; Bruchas et al.,
2006).
E3 Ubiquitin Ligases
While ubiquitination was long thought to control only protein
degradation, it has now become clear it also plays a role in
productive signal transduction cascades. β-Arrestins can act
as adapters for E3 ubiquitin ligases such as MDM2, which
mediates ubiquitination of p53 and as such plays a role in
DDR (Shenoy et al., 2001) by controlling p53 expression
levels. The complexes that β-arrestin and these E3 ligases
create, are essential for mediating ubiquitin-dependent signaling.
For instance, β-arrestins are essential in the ubiquitination
of receptors, where these scaffolds act on late endosomal
population as a lysosomal degradation signal for the receptor.
When focusing back on MDM2, ubiquitination of β-arrestin2
is also required for clathrin-mediated β2AR internalization
(Shenoy et al., 2001). However, AIP4 E3 ligases are necessary
for endosomal sorting of CXCR4, after which it can be
sorted to lysosomes (Marchese et al., 2003). For this sorting,
an interaction of β-arrestin1 with Signal transducing adapter
molecule 1 (STAM1) is necessary, which is part of the endosomal
sorting complex (Malik and Marchese, 2010). This connection
between β-arrestin1 with CXCR4 also appears in our interactome
metadata analysis of the β-arrestin1 interactome specifically
(Figures 1G,J).
Nuclear Factors
β-arrestin2 has been shown to possess the ability to inhibit
nuclear factor κB (NF-κB) signaling through the physical
stabilization of IKBα (NFKB inhibitor alpha) (Gao et al., 2004).
Next to β-arrestin2, its family co-member β-arrestin1 can
directly influence epigenetic modifications through a nuclear
interaction with histone acetylases and de-acetylases which
influence chromatin structure (Kang et al., 2005). Moreover,
β-arrestin1 is also necessary for endothelin-1-induced NF-κB
activation in ovarian cancer cells since Cianfrocca et al. (2014)
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discovered a previously unrecognized pathway dependent on
β-arrestin1 to sustain NF-κB signaling in ovarian cancer.
β-Arrestin can also control NF-κB-mediated signaling
through AT1aR activation, which recruits this scaffold protein.
This was analyzed in rat vascular smooth muscle cells. Genetic
knockdown of β-arrestin1 and 2 inhibited Ang II-induced p64
NF-κB nuclear localization. The internalization of the activated
AT1AR mediated by β-arrestin, stimulated the NF-κB signaling
pathway, engendered a nuclear localization of the transcription
factor and resulted in the initiation of COX-2 (Cytochrome
c oxidase subunit 2) protein synthesis. As such, this research
line linked receptor internalization with the NF-κB pathway
(Morinelli et al., 2013).
In addition, β-arrestin2 exerts anti-inflammatory action
through the prevention of NF-κB activation. This action is
mediated through the direct inhibition of p38 MAPK. On the
other hand, a simultaneous anti-inflammatory effect can also
be initiated through cAMP and PKA activation via G protein
signaling which exerts an inhibitory effect on NF-κB (Campo
et al., 2015). Such output signaling complexity reinforces the
need for a more in-depth understanding of the spatiotemporal
dynamics of GPCR signaling before rational design of engineered
efficacy drugs is feasible.
Receptors and G Protein Subunits
The epidermal growth factor receptor (EGFRs) can be
functionally transactivated by GPCRs as well as being
functionally regulated by β-arrestins, through the stimulation of
a transmembrane matrix metalloprotease which causes cleaving
of membrane bound EGF ligand (Noma et al., 2007). In addition
to this, it has become clear that β-arrestin can mediate non-
canonical G protein signaling, where they promote this novel
form of cell signaling by both the Parathyroid hormone 1 (PTH1)
(Wehbi et al., 2013) and V2 vasopressin receptor (Feinstein et al.,
2013) from cytoplasmic endosome structures. This effect was lost
after knockdown of β-arrestin (Feinstein et al., 2013).
The β2AR has been proposed to maintain an active
conformation, even in endosomes distant from the plasma
membrane, which has the ability to signal productively through G
proteins to generate cAMP (Irannejad et al., 2013). This suggests
that trafficking of the receptor to endosomes, via β-arrestins,
facilitates the stabilization of a receptor that is not necessarily
inactivated and ready to be recycled, but one that is still
able to activate G protein signaling. This signaling paradigm
appears to be facilitated by a Receptor – G protein – β-arrestin
complex (Wehbi et al., 2013), thus completely countering the
classic paradigm of β-arrestin as ‘arresting’ G protein signaling
(mentioned in see section “Introduction”).
β-Arrestin Dependent Signaling in
Therapeutic Development
Type 1 Parathyroid Hormone Receptor
β-Arrestin dependent signaling-selective ligands have been
investigating in the attempt to design precision ‘tailored efficacy’
therapies that possess a more focused efficacy with fewer off-
target side effects. Perhaps one of the best characterized arrestin
pathway-selective biased agonist is that mediated through
the type 1 human parathyroid hormone receptor (PTH1R).
The PTH1 receptor regulates calcium homeostasis and bone
metabolism. Gesty-Palmer et al. (2006) reported that [D-
Trp12,Tyr34]bovine PTH(7-34) showed β-arrestin bias, acting
as an inverse agonist for PTH1R-Gαs coupling (Appleton
et al., 2013). Intermittent administration of bPTH(7-34) in vivo
increased bone mass, osteoblast number, in the absence of
osteoclast proliferation and bone resorption. These effects are
in stark contrast to those engendered by similar treatment
with endogenous human PTH(1-34) [hPTH(1-34)], which is
the current conventional therapy for osteoporosis (Gesty-Palmer
et al., 2009). Research has subsequently demonstrated that this
diverse and effective functional activity in the PTH1R is mediated
through the creation of a highly-translatable molecular signature
of altered protein expression patterns that is dependent on a
functional β-arrestin2 signaling capacity (Gesty-Palmer et al.,
2013; Maudsley et al., 2015, 2016). This research has thus allowed
GPCR-based drug design to enter the phase of multidimensional
therapeutic targeting to engender highly selective long-lasting
proteomics-based remediation of equally complex disease protein
profiles.
µ-Opioid Receptor
The µ-opioid receptor (MOR) can be activated by both
endogenous enkaphalin peptides and xenobiotic opiates such
as morphine or fentanyl (Darcq and Kieffer, 2018). G protein
agonism and receptor internalization have been demonstrated
for enkephalins and the opiate etorphine, however a lack of
receptor agonist-induced internalization was found for the opiate
agonist morphine (Keith et al., 1996; Darcq and Kieffer, 2018).
This could be explained by the poor ability of morphine to
stimulate receptor phosphorylation and thus its recruitment of
β-arrestin (Zhang et al., 1998), and is hence a good example of
negative β-arrestin bias. This connection between β-arrestin and
opioid signaling was also extracted from our obtained β-arrestin
interactome dataset (Figures 1G–J). Despite this, mice lacking
β-arrestin2 demonstrated a marked increase and prolongation
of morphine-induced analgesia, indicating, notwithstanding its
bias, that morphine is capable of stimulating β-arrestin-mediated
desensitization (Bohn et al., 1999). This discovery indicates
that ligands showing strong bias away from β-arrestin, toward
G proteins, might offer enhanced analgesia, where it may be
possible to separate the therapeutic efficacy from the negative side
effects of such agents (Bruns et al., 2006; Schmid et al., 2017).
One such compound has been discovered, named herkinorin,
where it diverts signaling activities away from side effects, such
as tolerance, respiratory suppression and constipation, which
are mediated by β-arrestin2 (Bohn et al., 2000; Raehal et al.,
2005; Groer et al., 2007; Manglik et al., 2016; Schmid et al.,
2017). Furthermore, PZM21, a potent Gi activator showed
minimal β-arrestin2 recruitment, causing analgesic effects in
absence respiratory depression, and is as such another example
of β-arrestin independent therapeutics (Manglik et al., 2016).
Angiotensin II Type 1 Receptor
The AT1R possesses a strong trophic role in the control of blood
pressure and electrolyte homeostasis, and thus has been widely
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targeted in the strategic development of pharmacotherapeutic
treatment for hypertension via the employment of classical
‘antagonists’ such as valsartan and losartan. Ang II typically
signals through the AT1R via Gαq-mediated activation of
phospholipase C (PLC) and induces receptor phosphorylation
by GRKs, thus recruiting β-arrestin to the receptor. This
β-arrestin recruitment desensitizes Gαq signaling, causes
receptor internalization and induces non-G protein-dependent
β-arrestin signaling (Anborgh et al., 2000; Sakmar et al., 2002).
Sar1, Ile4, Ile8-AngII (SII) was identified as a perfectly β-arrestin
biased ligand (Holloway et al., 2002), stimulating β-arrestin
signals such as ERK1/2 activation in the absence of G protein
signaling (Wei et al., 2003; Ahn et al., 2004). Such discrete
signaling has been elegantly demonstrated both in vivo and in
cellulo. SII has been found to induce contractility via β-arrestin
signaling in isolated cardiac myocytes, indicating a significant
effect on cardiac function (Rajagopal et al., 2006). Several of
the SII-activated signaling pathways appear to be pro-survival,
cytoprotective, and/or proliferative, i.e., Src, ERK1/2, Akt,
and phosphatidylinositol-3-OH kinase (PI3K) (Lefkowitz and
Shenoy, 2005; Lefkowitz et al., 2006; DeWire et al., 2007), and are
thus worthy of further investigation for drug-development.
Moreover, a potent, selective β-arrestin biased ligand of
the AT1R has been recently discovered, i.e., TRV120027
(Sar-Arg-Val-Tyr-Ile-His-Pro-D-Ala-OH), which competitively
antagonizes G protein signaling through the AT1R, yet stimulates
β-arrestin recruitment, activating several kinase pathways in
a β-arrestin-dependent manner. This biased ligand increased
cardiomyocyte contractility in vitro. In vivo characterization of
the ligand, in rats, showed a reduction in mean arterial pressure,
and most importantly (and unlike other unbiased antagonists)
TRV120027 increased cardiac performance and preserved
cardiac stroke volume (Violin et al., 2010). Unfortunately, even
though this drug showed great promise, TRV120027 failed in the
clinical phase 2b. Such an initial setback is unlikely to diminish
further interest in refining the efficacy profile of GPCR-targeting
biased agents.
β-Adrenergic Receptor
Classical orthosteric βAR antagonists have long been employed
as effective pharmacotherapeutics for numerous cardiovascular
conditions including hypertension (Williams et al., 2004), angina
(Gibbons et al., 2003), and heart failure (Bristow, 2000).
They possess the ability to block the harmful G protein-
mediated effects of superfluous catecholamine stimulation
in the heart and other organs. The widely used βAR
‘blocker’ Carvedilol (Coreg R©) has been demonstrated to possess
unique survival benefits in congestive heart failure, through a
β-arrestin-selective pathway in absence of the Gαs-dependent
activation of adenylate cyclase (AC) (Wollert and Drexler, 2002;
Wisler et al., 2007). This bias potentially explains its unique
clinical effectiveness in heart failure and other cardiovascular
disorders.
While for some cardiovascular diseases most so-called
‘β-blockers’ (βAR antagonists) are effective, in others only
a subset of such agents exert favorable actions. The βAR
receptor has also been targeted to treat asthma, a chronic
inflammation of the airways. The use of glucocorticosteroids
and β2AR agonists represent the cornerstones of asthma therapy
(Thanawala et al., 2014). Recently however, research has been
performed into the possibility of using biased ligands in the
treatment of asthma. Studies have shown that nadolol and ICI-
118,551 are inverse agonists at βAR for both G protein- and
β-arrestin-dependent pathways. Interestingly, while carvedilol
and propranolol share this inverse agonistic activity, they can
still activate ERK1/2 through β-arrestin signaling (Galandrin
and Bouvier, 2006; Wisler et al., 2007). Further investigation
into murine models for asthma, showed that nadolol, but not
propranolol, reduced airway hyperresponsiveness, a functional
subset of the asthma symptomologies. This beneficial effect of
nadolol in comparison to propranolol is likely related to the
ability of the latter to activate ERK1/2 signaling. Thus, blocking
β-arrestin-mediated signaling via βAR might be advantageous
in asthma treatment (Walker et al., 2011; Thanawala et al.,
2014).
β-ARRESTIN IN AGING
With advancing age, as well as age-related pathophysiology, an
increased expression and functional impact has been shown for
β-arrestin and several other GPCR scaffolding proteins (e.g.,
GRKs) (Schutzer et al., 2001; Bychkov et al., 2008; Tsutsui
et al., 2008; Lu et al., 2017). This finding poses an interesting
pathophysiological question related to the ‘complexity theory’ of
aging. As we age there is proposed to be a global homeostatic
loss of complexity (Lipsitz and Goldberger, 1992; Manor and
Lipsitz, 2013; Sleimen-Malkoun et al., 2014), mediated by the
entropic breakdown of metabolic energy generation and damage
repair systems. However, simultaneous with this global reduction
homeostatic stability, it is likely that multiple compensatory
mechanisms, e.g., switching energy metabolism from the Type
II Diabetes mellitus (T2DM)-affected glucometabolic system
to less efficient systems such as fatty acid beta-oxidation or
ketogenesis, are instigated to attenuate damage due to the
loss of optimal signaling system efficiency. This aging-driven
increase in metabolic molecular signaling diversity results
in a counterintuitive rise in ‘allostatic’ complexity alongside
the loss of global homeostatic complexity (McEwen, 1998;
Karlamangla et al., 2002; Sturmberg et al., 2015; Shiels et al.,
2017). Therefore, at a receptor-based microcosmic level, do
the increasing levels of β-arrestin, with the resultant increase
in signaling diversity, represent perhaps the ‘tip of the spear’
of aging? Alterations in complexity and diversity of GPCR
systems will likely impact nearly all physiological systems
implicated in aging, thus an enhanced appreciation of how
altered GPCR signaling diversity controls the aging process
is vital for the future development of pharmacotherapeutics
with augmented efficacy profiles in the specific contexts of
stress and aging. As a caveat to this posit however, it is
likely that alterations in GPCR β-arrestin bias during age-
related pathology are not simply unilateral or unidirectional,
as signaling diversity from GPCRs may be vital for both
allostatic and homeostatic mechanisms. Thus, in addition
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to increased expression levels, decreases (reducing perhaps
excessive allostatic load engendered by GPCR bias) in β-arrestin
expression/functionality may also be important (Grange-Midroit
et al., 2002). To dissect this complex temporal relationship
between β-arrestin-mediated GPCR signaling diversity and the
physiological aging context, it is first important to define the
intersections between β-arrestin functionality and the major
pathophysiological domains of the natural (as well as aberrant)
aging process.
β-Arrestin Intersection With the
Hallmarks of Aging
Oxidative Stress
The elevated presence of ROS in nearly every cell in the
body needs to be countered to relieve the well-documented
phenomenon of age-related oxidative damage (Redman et al.,
2018). When the body is unable to balance these ROS with
antioxidants, oxidative stress and damage occurs, leading to
the deleterious modification of proteins, lipids, and nucleic
acids. β-Arrestin has been shown to regulate oxidative stress by
controlling NADPH oxidase 4 (NOX4), a major source of ROS
in the heart. It was demonstrated that β-arrestin knockdown
decreases ROS and NOX4 expression by 50% (Philip et al.,
2015). Accumulation of ROS after UV and hydrogen peroxide
(H2O2) treatment leads to the activation of multiple stress
kinase cascades, such as the apoptosis signal-regulating kinase
1 (ASK1) signaling pathways, and then induce cell apoptosis
(Tobiume et al., 1997; Chang et al., 1998; Ichijo, 1999; Morita
et al., 2001). Through ASK1, β-arrestins prevent down-stream
signaling and thus inhibits H2O2-induced cell apoptosis (Zhang
et al., 2009).
DNA Damage
One of the most scrutinized hallmarks of aging is the
accumulation of DNA damage. p53 is a central player in
DDRs, where this protein is upregulated and activated by
genotoxic stress. In cases of cellular stress, p53 induces an
active transcriptional response of effectors promoting apoptosis,
cell cycle arrest, senescence, and DNA repair (Speidel, 2015).
MDM2 is a ubiquitin E3 ligase that targets p53 for proteasomal
degradation (Haupt et al., 1997; Kubbutat et al., 1997). Hara
et al. (2011) demonstrated that β-arrestin1-mediated signaling
downstream of the β2AR, could trigger DNA damage and
suppress p53 expression, which adds up to the accumulation
of DNA damage. This by facilitating Akt-mediated activation
of MDM2 and promoting MDM2 association with, and
degradation of, p53, through its role as a scaffolding protein.
Further investigation into the link between β-arrestin1 and p53,
demonstrated an interaction between these two proteins in cellulo
and in vivo in the brain, where 50% of the binding between
β-arrestin1 and p53 occurs in the nucleus (Hara et al., 2011).
Metabolic Dysfunction
With respect to age-related somatic metabolic dysfunction,
perhaps the most prevalent are Metabolic Syndrome and
generic insulin resistance leading to T2DM (Bonomini et al.,
2015). In both of these dysfunctional conditions there is
a disruption of the ability/efficiency of insulin to stimulate
insulin receptor signaling and effectively mobilize and use
glucose as a primary energy source for mitochondrial oxidative
phosphorylation (Feng et al., 2011). β-Arrestin1, can scaffold
and recruit PI3K to the insulin growth factor-1 receptor
(IGF-1R) in an agonist-dependent manner, thus facilitating
the activation of PI3K and Akt. By doing so, β-arrestin1 is
capable of weakening insulin-induced degradation of insulin
receptor substrate-1 (IRS1) and thus promote downstream
insulin signaling. Furthermore, β-arrestin1 binds to MDM2,
as mentioned in Section “DNA Damage,” and competitively
inhibits MDM2-mediated IRS1 degradation, and in doing so
improves insulin sensitivity (Usui et al., 2004; Lefkowitz et al.,
2006).
β-Arrestin1 has also been implicated in insulin secretion
through the Glucagon-like peptide-1 receptor (GLP-1R), which
has been the focus for both new anti-diabetic and anti-
neurodegenerative therapies (Janssens et al., 2014). Sonoda et al.
(2008) reported that β-arrestin1 mediated the ability of GLP-1
to stimulate cAMP and insulin secretion in pancreatic β cells.
Moreover, a direct physical interaction between the receptor
and β-arrestin was found in cultured INS-1 pancreatic β cells
(Dalle et al., 2011). Quoyer et al. (2010) discovered that in
addition to this, β-arrestin1 can mediated GLP-1 anti-apoptotic
effects by phosphorylation of the pro-apoptotic protein Bad
through ERK1/2 activation (Quoyer et al., 2010). Broca et al.
(2009) reported that β-arrestin1 could control potentiation
of glucose-induced long-lasting ERK1/2 activation controlling
IRS2 expression, through the actions of pituitary adenylate
cyclase-activating polypeptide (PACAP) (Broca et al., 2009). This
year, Jones et al. (2018) indicated that compounds retaining
GLP-1R at the plasma membrane through a reduction in
β-arrestin recruitment were able to engender greater long-term
insulin release patterns. These compounds elicited glycemic
benefits in mice without related increases in signs of nausea
which often occurs with GLP-1 therapies (Jones et al.,
2018).
In addition to alterations of metabolism mediated by
glycoregulatory disruption, global metabolic functions in aging
are affected by changes in thyroid hormone activity. Thyroid
hormones serve to control the generic metabolic rate in the
body through the control of glucose/lipid/protein catabolism.
With advancing age however there is an increased prevalence of
hypothyroidism, which is furthermore associated with coronary
heart disease, heart failure and cardiovascular mortality (Gesing
et al., 2012). An animal model for hypothyroidism showed
unaltered β-arrestin1 expression in the heart, yet a decrease was
seen in the lung and an increase in the liver, this in contrast to
the expression of GRK5 which shows significant up-regulation
in lung and heart and a decrease in the liver shortly after birth.
This confirms an independent regulation of the expression of
these proteins and thus suggesting the presence of significant
‘active’ compensatory mechanisms (Penela et al., 2001). The
potential functional correlation of these changes in β-arrestin1
are highly nuanced, given the fact that this scaffolding protein acts
downstream of GRK’s in GPCR regulation (Michel-Reher et al.,
1993).
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Chronic Inflammation
Long-term uncontrolled inflammatory activity is a key trophic
facet in the aging process. A chronic pervasive form of
inflammation is so common among pathological aging
phenotypes that the generation of the novel portmanteau
description of this process as ‘inflammaging’ was warranted.
β-Arrestins have been shown to act as scaffold proteins or signal
transducers for key inflammatory signaling molecules in receptor
tyrosine kinases (RTKs) signal transduction pathways, such as
the NF-κB pathway (Gao et al., 2004). NF-κB is a ubiquitously
expressed transcription factor that regulated genes involved in
inflammation, immunity, and stress (Shoelson et al., 2003). The
inflammatory NF-κB system has also been recently implicated
in the basic metabolic control of the natural aging mechanism
itself (Zhang et al., 2013). Campo and co-workers recently
demonstrated that the anti-inflammatory action of β-arrestin2
appears to be mediated partially through the direct inhibition of
p38 MAPK which prevents the activation of NF-κB, and partially
through cAMP and PKA activation through G protein signaling,
which also exerts an inhibitory effect on NF-κB (Campo et al.,
2015).
Wang et al. (2015) reported that fenoterol, a βAR agonist used
for relieving sudden asthma attacks, by stimulating βARs to relax
bronchial smooth muscle, has the ability to inhibit 5-amino-1-
b-D-ribofuranosyl-imidazole-4-carboxamide (AICAR)-induced
AMPK activation and inflammatory cytokine production in cells.
The AMPK pathway is involved in regulating inflammation
in several cells lines (Wang et al., 2015). This inhibition, as
well as the attenuation of tumor necrosis factor α (TNF)-
α release, was abolished with the knockdown of β-arrestin2,
indicating that β-arrestin2 likely facilitates the anti-inflammatory
effects of fenoterol in AICAR-treated cells (Wang et al., 2016).
Du et al. (2014) investigated the pro-inflammatory activity of
fluoxetine (Prozac R©), where they found that this antidepressant
increased β-arrestin2 expression and enhanced the association
of β-arrestin2 with transforming growth factor beta-activated
kinase 1 (TAK1) binding protein 1 (TAB1) and disrupted the
TAK1-TAB1 interaction, which attenuates the IκB (inhibitor of
κB) degradation and NF-κB nuclear translocation (Du et al.,
2014).
Further research in the role of β-arrestins in inflammation,
has indicated that the anti- or pro-inflammatory dimensions of
β-arrestin2 activity could be dictated by its ubiquitination status,
which is linked to its ability to scaffold and localize activated
ERK1/2 to receptorsomes (Jean-Charles et al., 2016). This was
hypothesized since β-arrestin2 affects tumor necrosis factor
receptor-associated factor 6 (TRAF6) in an anti-inflammatory
manner, while physiologic β-arrestin2 promotes inflammation in
disorders such as atherosclerosis and neointimal hyperplasia. In
this specific context, the constitutive ubiquitination of β-arrestin2
furthermore augmented NFκB activation (Jean-Charles et al.,
2016).
β-Arrestin in Age-Related Disorders
Type II Diabetes Mellitus (T2DM)
The occurrence of T2DM increases with age, where the body
builds up an insulin resistance (linked to insulin receptor
desensitization mechanisms), as well as the presence of a
secretory dysfunction of the excess plasma-borne glucose (i.e.,
microvascular disease) (Matthaei et al., 2000; Taniguchi et al.,
2006). Recent studies have shown that the orphan receptor
GPR40 might be an attractive target to enhance insulin secretion
in T2DM patients. Research into the relationship of β-arrestin
and this receptor have shown that β-arrestin2, together with
GRK2, play an essential role in the regulation of agonist-mediated
internalization, but not of the constitutive GPR40 internalization
(Qian et al., 2014). This suggests that perhaps targeting and
modulating this GPR40 through β-arrestin2, thus influencing the
internalization, might be an interesting road to take, in treating
T2DM.
Additionally, there is a crosstalk between the insulin/Insulin-
like growth factor 1 receptors and signaling pathways including
G proteins and β-arrestin (Blair and Marshall, 1997; Lin et al.,
1998; Povsic et al., 2003; Ryall and Lynch, 2008). In diabetic mice,
β-arrestin2 expression is severely declined, moreover knockdown
of β-arrestin2 worsened insulin resistance, while administration
of β-arrestin2 could rescue this phenotype and restore insulin
sensitivity in the mice. Lastly, the formation of a new β-arrestin2
signal complex occurs after insulin stimulation. In this complex,
β-arrestin2 scaffolds Akt and Src to the insulin receptor directly.
Loss or dysfunction of β-arrestin2 disrupted the formation of
this novel signal complex and caused a disturbance of insulin
signaling in vivo, as such aiding in the development of insulin
resistance and thus the progression of T2DM (Luan et al.,
2009). Also, β-arrestin2 plays a central role in irisin-induced
glucose metabolism in T2DM by regulating the p38 MAPK
signaling (mentioned in see section “E3 Ubiquitin Ligases”),
which according to Pang et al. (2017) might present a novel
therapeutic target for diabetes.
Lastly, as mentioned in Section “Metabolic Dysfunction,”
biased GLP-1R targeted ligands, diverting the signaling away
from β-arrestin signaling, and allowing the GPL-1R to be retained
at the plasma membrane, have shown promise for the treatment
of metabolic dysfunction (Sonoda et al., 2008; Al-Sabah et al.,
2014). This was further investigated by Zhang et al. (2015) using
GLP-1R G protein-biased agonist called P5. In this research,
it was shown that this biased ligand promoted G protein
signaling comparable to GLP-1 and Exendin-4, yet demonstrated
a significantly reduced β-arrestin response. This bias away from
β-arrestin dependent signaling appears to be more effective than
Exendin-4 at correcting hyperglycemia and lowering hemoglobin
A1c levels in diabetic mice after chronic P5 treatment (Zhang
et al., 2015).
Age-Related Neurodegeneration
β-Arrestin2 has been shown to play a crucial role in the
regulation of neurotransmitter receptors in the brain that are
associated with the generation of age-related neurodegenerative
phenotypes (Grange-Midroit et al., 2002). With advancing
age, diverse and nuanced changes in β-arrestin expression
have been noted. For example, a decrease in β-arrestin2
density has been found, which also occurs for most brain
neurotransmitter receptors and specific G coupling proteins,
indicating that this decline in expression of both receptor
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and receptor regulatory proteins is a common consequence of
the senescent brain (Sastre et al., 2001). Alzheimer’s disease
is a neurodegenerative debilitating disorder, which has been
investigated thoroughly – unfortunately however no preventative
therapy has been discovered yet despite this research. All efforts
of helping AD patients are based on symptomatic treatments,
in an attempt to slow down the progression of the disorder.
Unfortunately, as AD is a neurodegenerative disorder, once
the patients display symptoms, the disease has likely already
progressed too far to be therapeutically reversed. Proteins being
targeted for drug development are amyloid β, γ-secretase and
the amyloid β precursor protein (APP). The aberrant processing
of these proteins has been identified as a hallmark of AD
development (Martin et al., 2013; Thathiah et al., 2013; Zhang
et al., 2017).
Nervous systems functions, such as learning and memory,
controlled by βAR are recently hypothesized to be mediated
by G protein-independent signaling pathways. Liu et al. (2015)
reported that memory retrieval induced the activation of
β-arrestin signaling through the β1AR. β-Arrestin allows the
stimulation of ERK signaling and protein synthesis, which, in
this situation, leads to post-memory retrieval restabilization (Liu
et al., 2015). In addition to this, β-arrestin2 knockout mice
exhibit impaired memory retrieval in novel object recognition
tests and in Morris Water Maze analyses. This reveals the
potential therapeutic value of β-arrestin-biased ligands in the
treatment of memory-related disorders (Liu et al., 2015).
Further investigation into this relationship between β-arrestin
and neurodegenerative disorders, has shown that β-arrestin2
expression is elevated in two independent cohorts of AD
patients (Thathiah et al., 2013), and genetic variation of
β-arrestin2 is associated with late-onset AD (Jiang et al.,
2014).
When analyzing the relationship between β-arrestin and the
AD biomarker protein amyloid β, β-arrestin2 overexpression
leads to an increase in amyloid β peptide generation, the opposite
was true for genetically silencing β-arrestin2 in vitro and in vivo
in β-arrestin2 knockout mice (Thathiah et al., 2013). Moreover,
β-arrestin2 has been shown to interact with GPR3 and β2AR
GPCRs, which have both been implicated in AD pathology
and mediate their effects on amyloid β generation. β-Arrestin2
also interacts with the anterior pharynx defective 1 homolog
A (APH1A) subunit, part of the γ-secretase complex, which
mediates the final catalytic step that liberates amyloid β from
its precursor protein APP, and as a such, lies central to many
amyloid β therapeutic strategies (De Strooper, 2003; Hur et al.,
2012; Thathiah et al., 2013). Further investigating this interaction
between β-arrestin2 and APH1A, the tri-cyclic antidepressant
amitriptyline (Elavil R©) has previously shown to cause strongly
neurotrophic pharmacological activities, and is thus a possible
treatment of neurodegenerative disorders such as AD. Acute
cellular treatment of human neurons showed alteration in the
physical interaction between the neurotrophic tyrosine kinase
receptor 2 (NTRK2), and APP, and APH1A and β-arrestin2,
suggesting that changes in this multi-protein complex may be
associated with the beneficial therapeutic actions of amitriptyline
(Martin et al., 2013).
Zhang et al. (2017) investigated the association of APP
with GPCRs – they found that APP interacted with α2AAR.
The association between these two proteins is promoted by
agonist stimulation, but competes with β-arrestin2 binding
to the receptor and thus negatively affects receptor arrestin-
dependent internalization and desensitization (Zhang et al.,
2017). The α2AAR plays an important role in controlling
norepinephrine release and response. This discovery that APP
can affect α2AAR internalization may have an impact on
modulation of noradrenergic activity and sympathetic tone, but
also affecting pain perception and decreasing epileptogenesis
and anxiety (Hein, 2006; Masse et al., 2006; Gyires et al.,
2009; Zhang et al., 2017). The noradrenergic system regulates
arousal, learning and memory, which has also been implicated
in regulating neuroinflammation (Ardestani et al., 2017). This
loss of the noradrenergic tone may underlie AD progression
at many levels (Ardestani et al., 2017; Zhang et al., 2017),
and has further also been investigated by Ardestani et al.
(2017) in the 5XFAD mouse model of AD. This research
group used a partial agonist of the β1AR, Xamoterol, which
restores the behavioral deficits of AD mouse models (Ardestani
et al., 2017). Xameterol has been demonstrated to show
bias away from the β-arrestin toward the cAMP pathway.
Moreover, Ardestani et al. (2017) looked for a potential
role of the partial agonist to counter neuroinflammation,
where chronic administration reduced mRNA expression of
neuroinflammatory markers, but also amyloid beta and tau
pathology, which are used as markers for AD development,
measured by regional immunohistochemistry (Ardestani et al.,
2017). This G protein-dependence was further investigated
by Yi and co-workers (Yi et al., 2017) – their work lead
to the development of a brain-permeable G protein-biased
β1AR ligand for the treatment of neurocognitive disorders
(Yi et al., 2017). This receptor is fundamentally involved
in the pathological features associated with AD, such as
the cognitive deficits, and regulation of neuroinflammatory
processes. These data therefore indicate that β1AR may be a
promising therapeutic target for AD, where its activation may
produce neuroprotective effects in neuroinflammatory disorders.
In their recent paper, Yi et al. (2017) identified a possible
functionally selective partial agonist for this receptor, namely
the molecule STD-101-D1, which shows high brain penetration
and inhibits TNFα. However, further research needs to be
performed in order to confirm its therapeutic potential (Yi et al.,
2017).
The cognitive deficit in AD is thought to be caused by the
degeneration of the cholinergic receptor system. This pathology
is thought to be linked to a loss of signaling through the
cholinergic M1-muscarinic receptor subtype. Current studies
offer an alternative mechanism involving the M3-muscarinic
receptor subtype that is expressed in numerous brain regions
including the hippocampus. The M3-muscarinic receptor
knockout mouse demonstrates a deficit in fear conditioning
learning and memory, which appears to be dependent on
receptor phosphorylation/arrestin signaling. This opens the
potential for biased M3-muscarinic receptor ligands that direct
phosphorylation/arrestin-dependent (non-G protein-dependent)
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signaling as being beneficial in cognitive disorders (Poulin et al.,
2010).
Osteoporosis
Human PTH regulates calcium homeostasis as well as bone
formation and resorption via activation of the PTH1R – as
such it is a possible target in treating the highly prevalent
age-related bone disorder osteoporosis (Gesty-Palmer et al.,
2005). Functions of arrestin in bone were first described
in UMR 106-H5, an osteoblastic cell line, where β-arrestin2
was found to be involved in PTH1R desensitization (Bliziotes
et al., 1996). Activated PTH1Rs recruit both β-arrestin1 and
2, which leads to the clathrin-dependent internalization of this
complex, and arrestin-dependent scaffolding of the ERK1/2
cascade (Ferrari et al., 1999; Vilardaga et al., 2002; Gesty-
Palmer et al., 2006). This ERK1/2 activation occurs via multiple
independent pathways, involving PKA, PKC and/or arrestins
(Verheijen and Defize, 1997; Lederer et al., 2000; Gesty-Palmer
et al., 2009). Thus, as previously mentioned, β-arrestins have
the ability to serve as multifunctional scaffolding proteins, in
addition to their desensitizing actions. In this context, β-arrestins
link the PTH1R to signaling molecules independently of classic
G protein-mediated second messenger-dependent pathways
(Bohinc and Gesty-Palmer, 2013). This ability to dissociate
arrestin- and G protein-dependent PTH1R signaling in bone
will likely influence future therapeutic design for osteoporosis
treatment.
We have previously mentioned the role for β-arrestin
in PTH signaling and in osteoporosis treatment (Gesty-
Palmer et al., 2006; Gesty-Palmer et al., 2009; Luttrell and
Gesty-Palmer, 2010). In addition to this, when PTH was
administered intermittently to β-arrestin knockout mice the
anabolic effects on the trabecular bone compartment were
blunted, indicating that the recruitment of arrestins may be
required to maintain a positive bone remodeling balance
(Ferrari et al., 2005; Kostenuik et al., 2007). Unlike PTH,
a β-arrestin biased PTH isoform (bPTH7-34) appears to
uncouple the beneficial anabolic effects of the PTH1R activation
from its catabolic and calcitropic negative side effects, thus
confirming an effective role for β-arrestin in osteoporosis
treatment (Gesty-Palmer and Luttrell, 2011; Luttrell et al.,
2018a). When we analyze the interacting proteins of β-arrestin1
and 2, this clinically-relevant connection to osteoporosis
reappears using the unbiased analysis of interactomic metadata
(Figures 1G–J).
Cardiovascular Disorders
While both β-arrestin1 and 2 are expressed throughout the
cardiovascular system, increases in β-arrestin2 expression have
been found in aged aortas (Gao et al., 2004; Aplin et al.,
2007). Additional research has indicated that this expression
alteration also occurs within aged hearts (Dobson et al., 2003).
Several GPCRs regulated by these two β-arrestins play immensely
important roles in cardiovascular physiology and homeostasis.
Contractility or cardiac function is tightly controlled by β1-
and β2AR at the plasma membrane of cardiac myocytes.
Cardiac structure and morphology on the other hand are
regulated by AT1Rs in the cardiac fibroblast and endothelial
cell membranes (Lymperopoulos and Bathgate, 2013). Ex vivo
studies revealed that SII (mentioned in see section “Angiotensin
II Type 1 Receptor”) can stimulate the contractility of isolated
cardiac myocytes via the AT1R and β-arrestin2 (Rajagopal
et al., 2006) and MAPK activation in perfused hearts (Aplin
et al., 2007). This data indicates that β-arrestin bias may
have a substantial impact in a physiological cardiovascular
setting.
Dobson et al. (2003) also observed a concomitant age-
dependent decrease in β1AR and adenylyl cyclase mRNAs.
Taking these results together, this strongly suggests that these
expressional changes in β1AR, adenylyl cyclase and β-arrestin
play a causal role in the declined adrenergic signaling seen in
aged hearts (Dobson et al., 2003). Moreover, in the context
of myocardial infarction in a mouse model of heart failure,
the molecular deletion of β-arrestin1 at the genetic level
leads to increased survival as well as decreased cardiac infarct
size, myocardia apoptosis, and adverse cardiac remodeling
(Bathgate-Siryk et al., 2014). β-Arrestin2, however, shows the
opposite, where it mediated EGFR transactivation by β1AR
and thus plays a protective role against cardiac apoptosis
(Noma et al., 2007). Carvedilol preferentially stimulates βAR
through β-arrestin. But even more than that, it induces
the transition of the β1AR from a classical Gαs-coupled
receptor to a Gαi-coupled receptor, thus stabilizing the
distinct β-arrestin-dependent receptor conformation. This Gαi
recruitment has not been shown for any other screened βAR
ligand so far, nor is it required for β-arrestin activation
by the β2AR (Wang et al., 2017). This advocates that the
concept of β-arrestin-bias may need to be refined to include
the selective bias of receptors toward distinct G protein
subtypes.
Additionally, the α1ARs in the cardiovascular system function
as stimulatory receptors and regulate vascular smooth muscle
contraction. As such they aid in the elevation of systemic
blood pressure through coupling to the Gαq/11 protein –
PLC – Ca2+ mobilization pathway (Piascik and Perez, 2001).
Antagonists of this receptor type, and thus biased ligands,
have the ability to lower blood pressure in hypertension,
hence these ligands biasing toward G protein can be used to
treat hypotension by causing vasoconstriction (Jensen et al.,
2011).
β-Arrestins also possess the ability to regulate oxidative
stress, one of the prime driving factors in metabolic aging,
in a NOX4-dependent manner, instigating an increase
fibrosis in heart failure. This was further investigated in
cardiac fibroblasts, where β-arrestin overexpression increased
mitochondrial superoxide production twofold, which stimulates
collagen deposition, thus leading to myocardial fibrosis, a
precursor to heart failure (Ichijo, 1999; Philip et al., 2015).
The recruitment of β-arrestin to the AT1R possibly engages a
pathway where Src phosphorylates and activates Akt, which
in turn phosphorylates endothelial nitric oxide synthase
(eNOS) (Haynes et al., 2003; Suzuki et al., 2006), which could
further provide a connection between AT1R-arrestin function
and cardiovascular tone via nitric oxide regulation (Violin
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et al., 2010). Consistent with β-arrestin bias of TRV120027,
eNOS activation by this ligand is eliminated by β-arrestin2
silencing. However, Ang II-stimulated eNOS phosphorylation
is reduced by approximately 50% after β-arrestin2 knockdown,
suggesting that the Ang II receptor can activate eNOS by both
β-arrestin2-dependent and –independent pathways (Violin et al.,
2010).
The endocrine peptide apelin has received considerable recent
pharmacotherapeutic attention due to its potential therapeutic
abilities for disorders such as pulmonary arterial hypertension
and heart failure (Yang et al., 2015). Infusion of apelin leads to
vasodilation, as well as cardiac inotropy without hypertrophy
(Tatemoto et al., 2001; Szokodi et al., 2002; Berry et al.,
2004; Ashley et al., 2005; Jia et al., 2006; Atluri et al., 2007;
Maguire et al., 2009; Japp et al., 2010; Perjes et al., 2014;
Brame et al., 2015). The predominant isoform in the human
cardiovascular system is [Pyr1] apelin-13 (Maguire et al., 2009).
Upon activation with its endogenous ligand, the apelin receptor
is rapidly internalized through β-arrestin (Zhou et al., 2003;
Lee et al., 2010). This receptor desensitization may therefore
limit clinical efficacy of apelin-based agents. By creating a G
protein-biased small molecule apelin agonist, Read et al. (2016)
hypothesized that they could provide a solution to this limitation.
Such apelin receptor modulators were shown to have beneficial
cardiovascular action compared to the native peptide in humans
in vivo (Ceraudo et al., 2014; Chen et al., 2014). One such
biased small molecule, CMF-019, has therefore been proposed
as an effective future biased receptor therapeutic (Read et al.,
2016).
Cancer
Next we will shortly discuss the role for β-arrestins in the
development of cancer. As a downstream signaler of GPCRs
and activator of tyrosine kinase Src it stands to reason
that these scaffolding proteins might play a role in cancer
development. The activation of the GPCR endothelin-A receptor
by endothelin 1 appears to play an important role in ovarian
tumorigeneses and advancement, through the recruitment of
β-arrestin. The role of this scaffold protein lies in the formation
of trimeric complexes through one of which is through Src-
interaction leading to transactivation of EGFR and β-catenin
tyrosine phosphorylation (Rosano et al., 2009). Additionally,
β-arrestin can contribute to β-catenin stabilization, which is part
of the cell invasion program, through a physical association
with axin. Silencing of β-arrestin1 and 2 completely nullifies
the involvement of β-arrestin in the relationship between
endothelin-A receptor and β-catenin pathway in this invasive
program. One antagonist, ZD4054, allows this abrogation
to take place and as such may open up new therapeutic
opportunities for the treatment of ovarian cancer (Rosano et al.,
2009).
The relationship between EGFR and β-arrestin1 has
further been analyzed by Buchanan et al. (2006) in
relation to colorectal carcinoma. The prostaglandin E2-
induced transactivation of EGFR in these cancer cells are
facilitated through a c-Src-dependent mechanism, which
regulates cell migration and differentiation, both of which
are important in tumor development. In their research,
Buchanan et al. (2006) found that the prostaglandin
E/β-arrestin1/c-Src signaling complex formation is crucial
in this transactivation of EGFR and thus implicates a functional
role for β-arrestin1 as a moderator of cell migration and
metastasis.
Furthermore, the involvement of β-arrestin signaling in IGF-
1R downstream signaling in Ewing’s sarcoma implicates that we
should focus on a ligand showing bias away from β-arrestin.
This was hypothesized as the association of the IGF-1R and
β-arrestin1 due to the anti-IGF-1R antibody figitumumab, which
has the following negative results: (i) receptor ubiquitination
and degradation, and (ii) a decrease in cell viability and ERK
signaling activation through β-arrestin1. As such, this signaling
bias, i.e., β-arrestin1 regulation, suggests a possible therapeutic
strategy to enhance response to anti-IGF-1R therapies (Zheng
et al., 2012).
In addition to the demonstration that the EGFR receptor
forms functional complexes with GPCR systems (Della Rocca
et al., 1999; Prenzel et al., 1999; Maudsley et al., 2000; Roudabush
et al., 2000), further GPCR-RTK associations, e.g., with platelet-
derived growth factor receptors (PDGFRs) were subsequently
shown to mediate a strong linkage between these signaling
domains (Conway et al., 1999; Maudsley et al., 2000; Waters
et al., 2003). PDGFR signaling has been strongly linked with
gastric cancer (Qian et al., 2018), gliomas (Heldin et al.,
2018), soft-tissue sarcomas (Vincenzi et al., 2017) and colorectal
cancer (Manzat Saplacan et al., 2017). As β-arrestins form
a crucial part of GPCR-based signaling it is not surprising
that they possess the ability to modulate PDGFR signaling
in concert with c-Src (Waters et al., 2005; Pyne and Pyne,
2017).
DISCUSSION
G protein coupled receptors are the most common molecular
targets of clinically-relevant drug therapies – at this moment
nearly 50% of all therapies are directed at the heterotrimeric
G protein signaling GPCR states (Ayoub, 2018). However,
it is now clear that the seven-transmembrane receptors can
signal through β-arrestins in a clinically-relevant manner. By
targeting GPCRs through their β-arrestin signaling, the number
of drugs can perhaps be doubled. In addition to increasing
the number of drugs, the specificity of these drug can also
increase, thus aiding in the development of true ‘precision
medicine,’ a medical model that proposes the customization
of therapeutics and healthcare, with medical treatments
being adapted to the individual patient or smaller patient
groups clustered by similar molecular signatures. It has also
become clear that ‘biased ligands’ can selectively activate
G protein and/or β-arrestin functions, thus eliciting novel
biological effects for even the best studied GPCRs (Violin and
Lefkowitz, 2007). In this review, we have focused on specific
β-arrestin functions, more specifically its important role in
aging, and thus the possibility in treating age-related disorders,
such as neurodegeneration, and cardiovascular disorders.
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It has become clear that depending on the goal of the
therapy, it is important to push the ‘bias’ toward β-arrestin,
as is the case for osteoporosis discussed in Sections “Type 1
Parathyroid Hormone Receptor” and “Osteoporosis,” or away
from β-arrestin, as is the case for the µ-opioid receptor
(see section “µ-Opioid Receptor”). While they have only
been recently identified, biased ligands have actually been
in pharmaceutical drug development for a long time, but
they were labeled as classical ‘antagonists’ (Andresen and
Luttrell, 2011). The most important question now for biased
ligand design is ‘how much bias is necessary for a successful
therapy?’ While 100% of β-arrestin bias will most likely cause
adverse effects, 60% bias might be ideal for a specific therapy.
Furthermore, should drugs be designed to incorporate, or avoid,
activation of the β-arrestin signaling pathways? We believe
that completely removing one of the two signaling pathways,
could be more harmful than advantageous (Maudsley et al.,
2012). The body has been designed to function through both
pathways, thus completely removing one or the other, could be
catastrophic.
G protein coupled receptors located at the plasma membrane
function as information channels running between the external
environment and the interior of the cell. This signal transduction
is based on the physical interaction of receptors with the
intracellular effectors after activation by the productive
interaction with the extracellular ligands. Additionally, it has
become clear that membrane receptors can assume multiple
conformations, which are each possibly capable of interacting
with a specific subset of possible effectors (Luttrell and Kenakin,
2011). Thus, it is important to note that GPCRs interact with
a broad range of diverse proteins other than heterotrimeric G
proteins or β-arrestins. It thus stands to reason that there may
be other effectors which could elicit specific signaling effects
as well. These factors may likely be scaffolding proteins that
may interact with GPCRs in diverse physiological contexts (e.g.,
oxidatively stressed), as opposed to the general ‘background’
receptor interactivity of G proteins or β-arrestins. As such, ligand
efficacy has truly become pluridimensional, which evokes more
possibilities for nuanced therapeutic design, but also increases
the complexity of ligand classification and design.
While ligand bias is now being widely explored and the
development of biased therapeutics has begun, since the
discovery of β-arrestin, no concerted systematic research has been
performed with respect to the possibility that there might be
more therapeutically-valuable scaffolding proteins which interact
with GPCRs. These scaffolders might thus be potent downstream
effectors and cause signaling cascades of their own just like
β-arrestin, i.e., sodium-hydrogen exchange regulatory factor 1
(NHERF1) (Maudsley et al., 2000), Multi-PDZ domain protein 1
(MUPP1) and GRK interacting transcript 2 (GIT2) (van Gastel
et al., 2018). The identification of these proteins might cause
an even larger increase in the discovery of more effective and
selective therapeutics. This allows us to believe that we are on
the verge of a new age of GPCR targeted pharmaceuticals that
will exploit the ligand bias to adapt drug efficacy by enhancing
therapeutically beneficial signals and blocking harmful ones
(Rajagopal et al., 2010).
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